Study
|
Population
|
Year of primary publication
|
Therapy
|
Total no.
|
No. with diabetes
|
Reference
|
---|
4S
|
Prior CHD
|
1994
|
Simvastatin 20–40 mg
|
4444
|
202
|
20, 38
|
CARE
|
Prior CHD
|
1996
|
Pravastatin 40 mg
|
4159
|
586
|
21
|
Post-CABG*
|
Prior CHD
|
1997
|
Lovastatin 40–80 mg vs 2.5–5 mg
|
1351
|
122
|
39, 40
|
LIPID
|
Prior CHD
|
1998
|
Pravastatin 40 mg
|
9014
|
1077
|
6, 23
|
GISSI-P*
|
Prior CHD
|
2000
|
Pravastatin 20 mg
|
4271
|
582
|
41
|
GREACE*
|
Prior CHD
|
2002
|
Atorvastatin 10–80 mg
|
1600
|
313
|
42
|
PROSPER
|
Mixed
|
2002
|
Pravastatin 40 mg
|
5804
|
623
|
43
|
ALLHAT-LLT*
|
Mixed
|
2002
|
Pravastatin 20–40 mg
|
10355
|
3638
|
27
|
HPS
|
Mixed
|
2003
|
Simvastatin 40 mg
|
20536
|
5963
|
24, 25
|
ASCOT-LLA
|
Mixed
|
2003
|
Atorvastatin 10 mg
|
10305
|
2532
|
26
|
WOSCOPS
|
Primary
|
1995
|
Pravastatin 40 mg
|
6595
|
76
|
22
|
AFCAPS/TexCAPS
|
Primary
|
1998
|
Lovastatin 20–40 mg
|
6605
|
1 55
|
44
|
CARDS
|
Primary
|
2004
|
Atorvastatin 10 mg
|
2838
|
2838
|
28
|
Total
|
–
|
–
|
Any statin
|
87877
|
18707
| |
VA-HIT
|
Prior CHD
|
1999
|
Gemfibrozil 1200 mg
|
2531
|
769
|
29, 30, 32
|
BIP
|
Prior CHD
|
2000
|
Bezafibrate 400 mg
|
3090
|
309
|
31
|
DAIS
|
Mixed
|
2001
|
Fenofibrate 200 mg
|
418
|
418
|
33
|
LEADER
|
Mixed
|
2002
|
Bezafibrate 400 mg
|
1568
|
268
|
45
|
SENDCAP
|
Primary
|
1998
|
Bezafibrate 400 mg
|
164
|
164
|
46
|
HHS
|
Primary
|
1992
|
Gemfibrozil 1200 mg
|
4081
|
135
|
14, 15
|
Total
|
–
|
–
|
Any fibrate
|
11852
|
2063
| |
- * No placebo used; lipid lowering compared with less treatment in Post-CABG study, with no treatment in GISSI-P study, and with usual care in ALLHAT-LLT and GREACE studies.
- CHD = coronary heart disease